Profiling cytotoxic microRNAs in pediatric and adult glioblastoma cells by high-content screening, identification and validation of miR-1300
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia
Our concept of cancer latency, the interval from when a cancer starts until it is diagnosed, has changed dramatically. A prior widely-used definition was the interval between an exposure to a cancer-causing substance and cancer diagnosis.
Looking for Multi-Biomarker Panel Signature in HER2-Negative Breast Cancer through TNM-Based Stages Using Systems Biology Techniques
Breast cancer as the second most common cause of death among women should be given an special attention for improving survival rates by considering early diagnosis and screening programmes. However, most of the patients with BC disease are diagnosed at late stages of the disease.
The most challenging part of NGS-based IGHV analysis in CLL concerns the interpretation of the findings rather than the analysis per se. ERIC and EuroClonality-NGS are working hard on addressing open issues and on standardization. See Davi et al., Leukemia 2020, doi: 10.1038/s41375-020-0923-9.